About CuraTeQ Biologics
CuraTeQ Biologics is a Healthcare company based in Hyderabad (India) founded in 2020. It develops high-quality biosimilars for oncology and immunology to enhance patient access worldwide. It operates on a B2B model. CuraTeQ Biologics has raised $190.39 million across 2 funding rounds. The company has 424 employees. Its Indian entity Curateq Biologics Private Limited reported revenue of ₹9.49 Cr. CuraTeQ Biologics offers products and services including Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar. Its focus areas include Biotechnology, Biosimilars, Regulatory and Development and Oncology and Immunology.
Company details
CuraTeQ Biologics focuses on developing and manufacturing biosimilars, particularly in oncology and immunology, using advanced facilities in Hyderabad, India. The company employs strategies like analytical biosimilarity and regulatory engagements to shorten development timelines and ensure high-quality, cost-effective products. They target global markets, including EU and emerging regions, to provide affordable therapies and improve health outcomes for patients suffering from debilitating illnesses.
- Headquarters Hyderabad, India
- Employees 424
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website curateqbio.com
- Social LinkedIn
- Legal Name Curateq Biologics Private Limited
- Date of Incorporation 25 Apr, 2020
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹9.49 Cr
FY 2025 · +3082% YoY
- Net Loss-₹812 Cr
FY 2025 · -8553% margin
- EBITDA-₹623 Cr
FY 2025 · -6562% margin
- Total Equity Funding$190.39M (USD)
in 2 rounds
- Latest Funding Round$189.86M (USD), Series A
Dec 2025
- Employee Count424
Associated legal entities of CuraTeQ Biologics
CuraTeQ Biologics operates through Curateq Biologics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Curateq Biologics Private Limited CIN U24110TG2020PTC140190 | Active | 25 Apr 2020 | Hyderabad, Telangana | ₹9.5 Cr | 424 | 6 | View details |
Products & Services of CuraTeQ Biologics
CuraTeQ Biologics offers a comprehensive portfolio of products and services, including Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar.
Biosimilar for treating breast cancer and other tumors
Biosimilar for managing bone diseases and related conditions
Biosimilar to stimulate white blood cell production
Funding Insights of CuraTeQ Biologics
CuraTeQ Biologics has successfully raised a total of $190.39M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $189.86 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $190.39M
- Total Rounds 2
- Last Round Series A — $189.86M
- First Round $526,379
(Mar 2025)
All 2 funding rounds of CuraTeQ Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $189.86M | Series A | – | – | – |
| Mar 2025 | $526,379 | Angel Round | – | – | – |
Board of directors of Curateq Biologics Private Limited (CuraTeQ Biologics)
Curateq Biologics Private Limited is the primary company behind CuraTeQ Biologics. The board of Curateq Biologics Private Limited currently have 3 directors; the longest-serving is Madan Mohan Reddy Mettu, appointed in 2020. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Madan Mohan Reddy Mettu DIN 01284266 | Director | 25 Apr 2020 | 6 yrs 6 mo | Curateq Biologics Private Limited |
| Sivakumaran Meenakshisunderam DIN 01284320 | Director | 25 Apr 2020 | 6 yrs 6 mo | Curateq Biologics Private Limited |
| Mylandlahalli Rammohan Ashwini DIN 10568862 | Director | 17 May 2024 | 2 yrs 5 mo | Curateq Biologics Private Limited |
Financials of CuraTeQ Biologics
Figures of Curateq Biologics Private Limited, the primary company behind CuraTeQ Biologics, for FY 2025. Revenue was ₹9.49 Cr (+3082% year on year). Net loss was -₹812 Cr (-8553% margin). EBITDA was -₹623 Cr (-6562% margin). Revenue has grown at a compounded annual rate of +78% over three years.
- ₹9.49 CrRevenue · FY 2025 · +3082% YoY
- -₹812 CrNet loss · -8553% margin
- -₹623 CrEBITDA · -6562% margin
- ₹102 CrPaid-up capital
- 424Employees (provident fund records)
- +78%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Curateq Biologics Private Limited are on its company page.
Detailed financial statements for CuraTeQ Biologics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CuraTeQ Biologics
3 dated milestones of CuraTeQ Biologics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded CuraTeQ Biologics is founded.
- Funding First funding round of $526K.
- Funding Latest funding round, Series A, of $189.9M.
Web traffic of CuraTeQ Biologics
The website of CuraTeQ Biologics (curateqbio.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 6% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as CuraTeQ Biologics (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curateq Biologics
Complete news archive for CuraTeQ Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CuraTeQ Biologics
CuraTeQ Biologics was founded in 2020 and raised its 1st funding round 5 years after it was founded.
CuraTeQ Biologics is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
CuraTeQ Biologics is a funded company, having raised a total of $190.39M across 2 funding rounds to date. The company's 1st funding round was a Angel Round of $526.38K, raised on Mar 2025.
CuraTeQ Biologics has 424 employees.
The primary company behind CuraTeQ Biologics, Curateq Biologics Private Limited, reported revenue of ₹9.49 Cr for FY 2025, up 3082% year on year.
CuraTeQ Biologics focuses on developing and manufacturing biosimilars, particularly in oncology and immunology, using advanced facilities in Hyderabad, India. The company employs strategies like analytical biosimilarity and regulatory engagements to shorten development timelines and ensure high-quality, cost-effective products. They target global markets, including EU and emerging regions, to provide affordable therapies and improve health outcomes for patients suffering from debilitating illnesses.
CuraTeQ Biologics offers Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar.
CuraTeQ Biologics operates through Curateq Biologics Private Limited.
The legal entities of CuraTeQ Biologics currently have 6 directors, including Madan Mohan Reddy Mettu, Sivakumaran Meenakshisunderam, Pravin Bhujanga Shettigar and others.